Abstract
The ultimate goal of Hodgkin’s disease (HD) therapy is no longer merely to achieve the cure of the patients, but to reach the Holy Grail of ‘uncomplicated cure.’ Actually, a cure associated with a low risk of benign complications might be acceptable in most cases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tubiana M, Henry-Amar M, Carde P et al. Towards comprehensive management tailored to prognostic factors of patients with clinical stage I and II in Hodgkin’s disease. The EORTC lymphoma group controlled clinical trials 1964–1987. Blood 1989; 73: 47–56.
Hohl RJ, Schlilsky RL. Non malignant complications of therapy for Hodgkin’s disease. Hematology/Oncology Clinics of North America 1989; 3: 331–43.
Cosset JM, Henry-Amar M, Burgers JMV et al. Late radiation injuries of the gastro-intestinal tract in the H2 and H5 EORTC Hodgkin’s disease trials: Emphasis on the role of exploratory laparotomy and fractionation. Radiother Oncol 1988; 13: 618.
Gallez-Marchal D, Fayolle M, Henry-Amar M et al. Radiation injuries of the gastro-intestinal tract in Hodgkin’s disease: The role of exploratory laparotomy and fractionation. Radiother Oncol 1984; 2: 93–9.
Thames HD, Hendry JH. Fractionation in radiotherapy. London: Taylor and Francis, 1987.
Cosset JM, Henry-Amar M, Girinsky T et al. Late toxicity of radiotherapy in Hodgkin’s disease: The role of fraction size. Acta Oncologica 1988; 27: 113–29.
Host H, Vale JR. Lung function after mantle field irradiation in Hodgkin’s disease. Cancer 1973; 32: 328–32.
Evans RF, Sagerman RH, Ringrose TL et al. Pulmonary function following mantle field irradiation for Hodgkin’s disease. Radiology 1974; 111: 729–31.
Watchie J, Coleman CN, Raffin TA et al. Minimal long term cardiopulmonary dysfunction following treatment for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1989; 16: 79–84.
Smith LM, Mendenhall NP, Cicale MJ et al. Results of a prospective study evaluating the effects of mantle irradition on pulmonary function. Int J Radiat Oncol Biol Phys 1989; 16: 7984.
Cosset JM, Henry-Amar M, Thomas J et al. Increased pulmonary toxicity in the ABVD arm of the EORTC H6-U trial. Proc Am Soc Clin Oncol 1989; 8: 253.
Zucali R, Pagnoni AM, Zanini M et al. Radiobiological and spirometric evaluation of mediastinal and pulmonary late effects after radiotherapy and chemotherapy for Hodgkin’s disease. J Eur Radiother 1981; 2: 169–76.
Boivin JF, Hutchison GB. Coronary heart disease mortality after irradiation of Hodgkin’s disease. Cancer 1982; 49: 24705.
Pohjola-Sintonen S, Totterman KJ, Salmo M et al. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer 1987; 60: 31–7.
Hancock SL, Hoppe RT, Horning SJ et al. Intercurrent death after Hodgkin’s disease therapy in radiotherapy and adjuvant MOPP trials. Ann Int Med 1988; 109: 183–9.
Rijswijk REN, Verbeek J, Haanen C et al. Major complications and causes of death in patients treated for Hodgkin’s disease. J Clin Oncol 1987; 5: 1624–33.
Cosset JM, Henry-Amar M, Pellae Cosset B et al. Pericarditis and myocardial infarctions after Hodgkin’s disease therapy at the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys 1990 (in press).
Corn BW, Trock BJ, Goodman RL. Irradiation-related ischaemic heart disease. J Clin Oncol 1990; 8: 741–50.
Henry-Amar M, Somers R. Long-term survival in early stages Hodgkin’s disease: The EORTC experience. In: Treatment Strategy in Hodgkin’s disease, Somers R, Henry-Amar M, Meerwaldt JH, Carde P (eds). Colloque INSERM no 196. London, Paris: INSERM/John Libbey Eurotext, 1990; 151–66.
Henry-Amar M. Risk of second cancer after therapy for early stage Hodgkin’s disease: The EORTC experience. Int J Radiat Oncol Biol Phys 1990 (in press).
Henry-Amar M, Pellae-Cosset B, Bayle-Weisgerber C et al. Risk of secondary acute leukemia and preleukemia after Hodgkin’s disease. The Institut Gustave-Roussy experience. In: New aspects in the diagnosis and treatment of Hodgkin’s disease. Diehl V, Pfreundschuh M, Diehl V, 1989; 117: 270–83.
Pedersen-Bjergaard J, Specht L, Larsen SO et al. Risk of therapy-related leukemia and preleukemia after Hodgkin’s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987; ii: 83–88.
Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin’s disease. N Engl J Med 1990; 322: 7–13.
Van Leeuwen FE, Somers R, Hart AAM. Splenectomy in Hodgkin’s disease and second leukemia. Lancet 1987; 2: 2101.
Leeuwen FE, Somers R, Tall BG et al. Increased risk of lung cancer, non-Hodgkin’s lymphoma, and leukemia following Hodgkin’s disease. J Clin Oncol 1989; 7: 1046–58.
Velden JW, Putten WL, Gurnee VF et al. Subsequent development of acute non-lymphocytic leukemias in patients treated for Hodgkin’s disease. Int J Cancer 1988; 42: 252–5.
Henry-Amar M, Somers R. Survival outcome after Hodgkin disease. A report from the International Database on Hodgkin disease (IDHD) Seminars in Oncology 1990 (in press).
Somers R, Henry-Amar M, Meerwaldt JH, Carde P (eds). Treatment Strategy in Hodgkin’s disease. Statistical report, part X. Colloque INSERM no 196. London, Paris: INSERM/John Libbey Eurotext, 1990; 381–418.
Author information
Authors and Affiliations
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Cosset, J.M., Henry-Amar, M., Meerwaldt, J.H., EORTC Lymphoma Cooperative Group. (1991). Long-term toxicity of early stages of Hodgkin’s disease therapy: The EORTC experience. In: Ultmann, J.E., Samuels, B.L. (eds) Annals of Oncology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7305-4_13
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7305-4_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7294-1
Online ISBN: 978-1-4899-7305-4
eBook Packages: Springer Book Archive